Understanding the diagnosis and treatment of early and locally advanced non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather real-world evidence regarding the diagnostic and therapeutic pathways for patients with non-small cell lung cancer (NSCLC) in early and locally advanced stages. It focuses on patients who have undergone curative surgery or radiotherapy between January 2018 and June 2019, analyzing their treatment outcomes and follow-up data until January 2021. The study addresses the variability in treatment approaches across different regions and medical centers, highlighting the need for a standardized strategy in managing NSCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with stage I-III NSCLC who have received curative surgery or radiotherapy between January 2018 and June 2019 with available follow-up through January 2021
2. Adult patients (aged ≥ 18 years) at the moment of diagnosis
3. Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent form; privacy Form (ICF). In case of deceased or untraceable patient the investigator before collecting data shall demonstrate and report all necessary measures adopted to contact the patient.

Exclusion Criteria:

1. Patients without availability of medical charts or information required
2. Enrollment in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.

Where it's running

• AOU Careggi
  Florence, Italy Recruiting
• IRCCS Policlinico S. Martino
  Genova, Italy Recruiting
• IRCCS Ospedale San Raffaele
  Milan, Italy Recruiting
• Istituto Clinico Humanitas
  Milan, Italy Recruiting
• AOU Vanvitelli
  Naples, Italy Recruiting
• A.O.U. Maggiore della Carità di Novara
  Novara, Italy Recruiting

Study contacts

• Study coordinator: Daniele Righi, PM
• Email: d.righi@yghea.it
• Phone: +39 051 5878211

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BIO 300 with thoracic radiation for early-stage non-small cell lung cancer and interstitial lung disease

  This trial will test whether adding BIO 300 to thoracic radiation lowers the chance of pneumonitis in people with stage I–II non-small cell lung cancer who also have interstitial lung disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07323732

• Combining treatments for advanced lung cancer after initial therapy

  This study is testing if adding Tremelimumab and more chemotherapy to the usual treatment can help people with advanced lung cancer do better after their initial therapy.

  Recruiting Phase 3 Stanford University · Stanford, California · NCT04585490

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Adaptive Chemotherapy for PD-L1 High Resectable NSCLC: A Chemo-PHREE Trial

  This study tests cemiplimab in adults with resectable non-small cell lung cancer to see if surgery can be pursued without preceding chemotherapy for some patients.

  Recruiting Phase 2 University of Maryland, Baltimore · Indianapolis, Indiana and 4 other locations · NCT07746388

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.